Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. [electronic resource]
Producer: 20080108Description: 333-8 p. digitalISSN:- 0300-2977
- Alemtuzumab
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- administration & dosage
- Antigens, CD -- drug effects
- Antigens, Neoplasm -- drug effects
- Aspergillosis -- chemically induced
- CD52 Antigen
- Drug Evaluation
- Drug Resistance, Neoplasm
- Glycoproteins -- drug effects
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Medical Records
- Netherlands
- Opportunistic Infections -- chemically induced
- Pneumonia, Pneumocystis -- chemically induced
- Remission Induction
- Retrospective Studies
- Surveys and Questionnaires
- Treatment Outcome
- Vidarabine -- analogs & derivatives
No physical items for this record
Publication Type: Evaluation Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.